The Switch Study evaluates the efficacy and safety of albiglutide, a GLP-1 receptor agonist, in combination with insulin glargine for patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled on a basal-bolus insulin regimen. Given the increasing prevalence of T2DM and the demand for effective treatment options, this study positions GlaxoSmithKline (GSK) to strengthen its portfolio in the diabetes market. The competitive landscape includes established therapies such as insulin lispro and other GLP-1 receptor agonists, which may pose challenges in market penetration. Successful outcomes could enhance GSK's market share and provide leverage in negotiations with payers. Diligence should focus on the safety profile and potential for adverse events, particularly hypoglycemia, which could impact market acceptance.